Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.merckvaccines.com › mmrM-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) |...

   www.merckvaccines.com › mmr

   • Zapisane w pamięci cache

   M-M-R ® II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R ® II is administered at 12 to 15 months of age and the second dose of M-M-R ® II is administered at 4 to 6 years of age.

   • Im Dosage and Administration

     Im Dosage and Administration - M-M-R®II (Measles, Mumps, and...

   • Revamp Update Mmrv Family

     Hypersensitivity: ProQuad, M-M-R ® II, and VARIVAX are...

   • Frequently Asked Questions

     Frequently Asked Questions - M-M-R®II (Measles, Mumps, and...

   • Clinical Data

     Clinical Data - M-M-R®II (Measles, Mumps, and Rubella Virus...

   • ACIP Recommendations

     ACIP Recommendations - M-M-R®II (Measles, Mumps, and Rubella...

   • Storage and Handling

     Storage and Handling - M-M-R®II (Measles, Mumps, and Rubella...

2. en.wikipedia.org › wiki › Mumps_vaccineMumps vaccine - Wikipedia

   en.wikipedia.org › wiki › Mumps_vaccine

   • Zapisane w pamięci cache

   Mumps vaccines are vaccines which prevent mumps. [1] When given to a majority of the population they decrease complications at the population level. [1] Effectiveness when 90% of a population is vaccinated is estimated at 85%. [2] Two doses are required for long term prevention. [1] The initial dose is recommended between 12 and 18 months of ...

3. www.fda.gov › vaccines-blood-biologics › vaccinesMeasles, Mumps and Rubella Virus Vaccine Live | FDA

   www.fda.gov › vaccines-blood-biologics › vaccines

   • Zapisane w pamięci cache

   22 sie 2023 · Manufacturer: Merck Sharp & Dohme LLC. Indication: M-M-R II is a vaccine indicated for active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age...

4. www.ema.europa.eu › en › medicinesM-M-RVaxPro - European Medicines Agency (EMA)

   www.ema.europa.eu › en › medicines

   • Zapisane w pamięci cache

   M-M-RVaxPro is a vaccine used to protect adults and children aged 12 months or older against measles, mumps, and rubella (German measles). Under some special circumstances, it can also be used in babies as young as nine months.

5. www.ema.europa.eu › en › documentsM-M-RVAXPRO, INN-Measles, mumps, and rubella vaccine (live)

   www.ema.europa.eu › en › documents

   M-M-RvaxPro is indicated for simultaneous vaccination against measles, mumps and rubella in individuals from 12 months of age (see section 4.2). M-M-RvaxPro can be administered to infants from 9 months of age under special circumstances (see

6. www.fda.gov › vaccines-blood-biologics › priorixPRIORIX | FDA - U.S. Food and Drug Administration

   www.fda.gov › vaccines-blood-biologics › priorix

   • Zapisane w pamięci cache

   1 lip 2022 · Manufacturer: GlaxoSmithKline Biologicals SA. Indications: For active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. Product...

7. www.ema.europa.eu › en › documentsM-M-RVAXPRO, INN- Measles, Mumps and Rubella Vaccine (Live)

   www.ema.europa.eu › en › documents

   M-M-RVAXPRO is indicated for simultaneous vaccination against measles, mumps and rubella in individuals from 12 months of age. Measles (rubeola) is caused by a paramyxovirus of the genus Morbillivirus and is transmitted from person to person via aerosolized or large respiratory infectious droplets.